APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sustained-release Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Sustained-release Medicine Market Outlook and Growth Opportunities 2026

21 December 2025196 pages

Choose your research edition.

Industry ResearchSustained-release Medicine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Sustained-release Medicine Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Sustained-release Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sustained-release Medicine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Sustained-release Medicine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Sustained-release Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Sustained-release Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sustained-release Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sustained-release Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Sustained-release Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Sustained-release Medicine market include Zhuhai Rundu Pharmaceutical, Endo Pharmaceuticals, Takeda, Shanghai Shyndec Pharmaceutical, Sanofi, Johnson & Johnson, Novartis, Pfizer and China Res Double-Crane, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Sustained-release Medicine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sustained-release Medicine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sustained-release Medicine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Sustained-release Medicine market.

Sustained-release Medicine Segment by Company

Zhuhai Rundu Pharmaceutical

Endo Pharmaceuticals

Takeda

Shanghai Shyndec Pharmaceutical

Sanofi

Johnson & Johnson

Novartis

Pfizer

China Res Double-Crane

Bayer

AbbVie

AstraZeneca

Collegium Pharmaceutical, Inc

Sustained-release Medicine Segment by Type

Original Ground Medicine

Generic Medicine

Sustained-release Medicine Segment by Application

Hospital

Drugstore

Other

Sustained-release Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Sustained-release Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Sustained-release Medicine key companies, revenue, market share, and recent developments.

3. To split the Sustained-release Medicine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Sustained-release Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Sustained-release Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Sustained-release Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained-release Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sustained-release Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained-release Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sustained-release Medicine industry.

Chapter 3: Detailed analysis of Sustained-release Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Sustained-release Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Sustained-release Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Sustained-release Medicine Industry Trends Table 2. Sustained-release Medicine Industry Drivers Table 3. Sustained-release Medicine Industry Opportunities and Challenges Table 4. Sustained-release Medicine Industry Restraints Table 5. Global Sustained-release Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Sustained-release Medicine Revenue Share by Company (2021-2026) Table 7. Global Sustained-release Medicine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Sustained-release Medicine Key Company Manufacturing Base & Headquarters Table 9. Global Sustained-release Medicine Company, Product Type & Application Table 10. Global Sustained-release Medicine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Sustained-release Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Original Ground Medicine Table 15. Significant Companies of Generic Medicine Table 16. Global Sustained-release Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Sustained-release Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Sustained-release Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Sustained-release Medicine Sales Value Share by Type (2021-2026) Table 20. Global Sustained-release Medicine Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Drugstore Table 23. Significant Companies of Other Table 24. Global Sustained-release Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Sustained-release Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Sustained-release Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Sustained-release Medicine Sales Value Share by Application (2021-2026) Table 28. Global Sustained-release Medicine Sales Value Share by Application (2027-2032) Table 29. Global Sustained-release Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Sustained-release Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Sustained-release Medicine Sales Value Share by Region (2021-2026) Table 32. Global Sustained-release Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Sustained-release Medicine Sales Value Share by Region (2027-2032) Table 34. Global Sustained-release Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Sustained-release Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Sustained-release Medicine Sales Value Market Share by Country (2021-2026) Table 37. Global Sustained-release Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Sustained-release Medicine Sales Value Market Share by Country (2027-2032) Table 39. Zhuhai Rundu Pharmaceutical Company Information Table 40. Zhuhai Rundu Pharmaceutical Business Overview Table 41. Zhuhai Rundu Pharmaceutical Sustained-release Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Zhuhai Rundu Pharmaceutical Sustained-release Medicine Product Portfolio Table 43. Zhuhai Rundu Pharmaceutical Recent Development Table 44. Endo Pharmaceuticals Company Information Table 45. Endo Pharmaceuticals Business Overview Table 46. Endo Pharmaceuticals Sustained-release Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Endo Pharmaceuticals Sustained-release Medicine Product Portfolio Table 48. Endo Pharmaceuticals Recent Development Table 49. Takeda Company Information Table 50. Takeda Business Overview Table 51. Takeda Sustained-release Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Takeda Sustained-release Medicine Product Portfolio Table 53. Takeda Recent Development Table 54. Shanghai Shyndec Pharmaceutical Company Information Table 55. Shanghai Shyndec Pharmaceutical Business Overview Table 56. Shanghai Shyndec Pharmaceutical Sustained-release Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Shanghai Shyndec Pharmaceutical Sustained-release Medicine Product Portfolio Table 58. Shanghai Shyndec Pharmaceutical Recent Development Table 59. Sanofi Company Information Table 60. Sanofi Business Overview Table 61. Sanofi Sustained-release Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Sanofi Sustained-release Medicine Product Portfolio Table 63. Sanofi Recent Development Table 64. Johnson & Johnson Company Information Table 65. Johnson & Johnson Business Overview Table 66. Johnson & Johnson Sustained-release Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Johnson & Johnson Sustained-release Medicine Product Portfolio Table 68. Johnson & Johnson Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Sustained-release Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Novartis Sustained-release Medicine Product Portfolio Table 73. Novartis Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Sustained-release Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer Sustained-release Medicine Product Portfolio Table 78. Pfizer Recent Development Table 79. China Res Double-Crane Company Information Table 80. China Res Double-Crane Business Overview Table 81. China Res Double-Crane Sustained-release Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. China Res Double-Crane Sustained-release Medicine Product Portfolio Table 83. China Res Double-Crane Recent Development Table 84. Bayer Company Information Table 85. Bayer Business Overview Table 86. Bayer Sustained-release Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Bayer Sustained-release Medicine Product Portfolio Table 88. Bayer Recent Development Table 89. AbbVie Company Information Table 90. AbbVie Business Overview Table 91. AbbVie Sustained-release Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. AbbVie Sustained-release Medicine Product Portfolio Table 93. AbbVie Recent Development Table 94. AstraZeneca Company Information Table 95. AstraZeneca Business Overview Table 96. AstraZeneca Sustained-release Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. AstraZeneca Sustained-release Medicine Product Portfolio Table 98. AstraZeneca Recent Development Table 99. Collegium Pharmaceutical, Inc Company Information Table 100. Collegium Pharmaceutical, Inc Business Overview Table 101. Collegium Pharmaceutical, Inc Sustained-release Medicine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Collegium Pharmaceutical, Inc Sustained-release Medicine Product Portfolio Table 103. Collegium Pharmaceutical, Inc Recent Development Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Sustained-release Medicine Product Image Figure 2. Global Sustained-release Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sustained-release Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Sustained-release Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Original Ground Medicine Image Figure 8. Generic Medicine Image Figure 9. Global Sustained-release Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Sustained-release Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Sustained-release Medicine Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Drugstore Image Figure 14. Other Image Figure 15. Global Sustained-release Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Sustained-release Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Sustained-release Medicine Sales Value Share by Application (2021-2032) Figure 18. Global Sustained-release Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Sustained-release Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Sustained-release Medicine Sales Value (2021-2032) & (US$ Million) Figure 21. North America Sustained-release Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Sustained-release Medicine Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Sustained-release Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Sustained-release Medicine Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Sustained-release Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Sustained-release Medicine Sales Value (2021-2032) & (US$ Million) Figure 27. South America Sustained-release Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Sustained-release Medicine Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Sustained-release Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Sustained-release Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Original Ground Medicine
  • Generic Medicine
Applications
  • Hospital
  • Drugstore
  • Other
Companies covered
  • Zhuhai Rundu Pharmaceutical
  • Endo Pharmaceuticals
  • Takeda
  • Shanghai Shyndec Pharmaceutical
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • China Res Double-Crane
  • Bayer
  • AbbVie
  • AstraZeneca
  • Collegium Pharmaceutical, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Sustained-release Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Sustained-release Medicine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Sustained-release Medicine Market Dynamics
  1. 2.1 Sustained-release Medicine Industry Trends
  2. 2.2 Sustained-release Medicine Industry Drivers
  3. 2.3 Sustained-release Medicine Industry Opportunities and Challenges
  4. 2.4 Sustained-release Medicine Industry Restraints
3 Sustained-release Medicine Market by Company
  1. 3.1 Global Sustained-release Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Sustained-release Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Sustained-release Medicine Company Ranking (2024-2026)
  4. 3.4 Global Sustained-release Medicine Company Manufacturing Base and Headquarters
  5. 3.5 Global Sustained-release Medicine Company Product Type and Application
  6. 3.6 Global Sustained-release Medicine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Sustained-release Medicine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Sustained-release Medicine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Sustained-release Medicine Market by Type
  1. 4.1 Sustained-release Medicine Type Introduction
  2. 4.1.1 Original Ground Medicine
  3. 4.1.2 Generic Medicine
  4. 4.2 Global Sustained-release Medicine Sales Value by Type
  5. 4.2.1 Global Sustained-release Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Sustained-release Medicine Sales Value by Type (2021-2032)
  7. 4.2.3 Global Sustained-release Medicine Sales Value Share by Type (2021-2032)
5 Sustained-release Medicine Market by Application
  1. 5.1 Sustained-release Medicine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drugstore
  4. 5.1.3 Other
  5. 5.2 Global Sustained-release Medicine Sales Value by Application
  6. 5.2.1 Global Sustained-release Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Sustained-release Medicine Sales Value by Application (2021-2032)
  8. 5.2.3 Global Sustained-release Medicine Sales Value Share by Application (2021-2032)
6 Sustained-release Medicine Regional Value Analysis
  1. 6.1 Global Sustained-release Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sustained-release Medicine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Sustained-release Medicine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Sustained-release Medicine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Sustained-release Medicine Sales Value (2021-2032)
  7. 6.3.2 North America Sustained-release Medicine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Sustained-release Medicine Sales Value (2021-2032)
  10. 6.4.2 Europe Sustained-release Medicine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Sustained-release Medicine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Sustained-release Medicine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Sustained-release Medicine Sales Value (2021-2032)
  16. 6.6.2 South America Sustained-release Medicine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Sustained-release Medicine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Sustained-release Medicine Sales Value Share by Country, 2025 VS 2032
7 Sustained-release Medicine Country-level Value Analysis
  1. 7.1 Global Sustained-release Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Sustained-release Medicine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Sustained-release Medicine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Sustained-release Medicine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Sustained-release Medicine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Sustained-release Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Sustained-release Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhuhai Rundu Pharmaceutical
  2. 8.1.1 Zhuhai Rundu Pharmaceutical Company Information
  3. 8.1.2 Zhuhai Rundu Pharmaceutical Business Overview
  4. 8.1.3 Zhuhai Rundu Pharmaceutical Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhuhai Rundu Pharmaceutical Sustained-release Medicine Product Portfolio
  6. 8.1.5 Zhuhai Rundu Pharmaceutical Recent Developments
  7. 8.2 Endo Pharmaceuticals
  8. 8.2.1 Endo Pharmaceuticals Company Information
  9. 8.2.2 Endo Pharmaceuticals Business Overview
  10. 8.2.3 Endo Pharmaceuticals Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Endo Pharmaceuticals Sustained-release Medicine Product Portfolio
  12. 8.2.5 Endo Pharmaceuticals Recent Developments
  13. 8.3 Takeda
  14. 8.3.1 Takeda Company Information
  15. 8.3.2 Takeda Business Overview
  16. 8.3.3 Takeda Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Takeda Sustained-release Medicine Product Portfolio
  18. 8.3.5 Takeda Recent Developments
  19. 8.4 Shanghai Shyndec Pharmaceutical
  20. 8.4.1 Shanghai Shyndec Pharmaceutical Company Information
  21. 8.4.2 Shanghai Shyndec Pharmaceutical Business Overview
  22. 8.4.3 Shanghai Shyndec Pharmaceutical Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Shyndec Pharmaceutical Sustained-release Medicine Product Portfolio
  24. 8.4.5 Shanghai Shyndec Pharmaceutical Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Sustained-release Medicine Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Johnson & Johnson
  32. 8.6.1 Johnson & Johnson Company Information
  33. 8.6.2 Johnson & Johnson Business Overview
  34. 8.6.3 Johnson & Johnson Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Johnson & Johnson Sustained-release Medicine Product Portfolio
  36. 8.6.5 Johnson & Johnson Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Sustained-release Medicine Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Sustained-release Medicine Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 China Res Double-Crane
  50. 8.9.1 China Res Double-Crane Company Information
  51. 8.9.2 China Res Double-Crane Business Overview
  52. 8.9.3 China Res Double-Crane Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 China Res Double-Crane Sustained-release Medicine Product Portfolio
  54. 8.9.5 China Res Double-Crane Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bayer Sustained-release Medicine Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 AbbVie
  62. 8.11.1 AbbVie Company Information
  63. 8.11.2 AbbVie Business Overview
  64. 8.11.3 AbbVie Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AbbVie Sustained-release Medicine Product Portfolio
  66. 8.11.5 AbbVie Recent Developments
  67. 8.12 AstraZeneca
  68. 8.12.1 AstraZeneca Company Information
  69. 8.12.2 AstraZeneca Business Overview
  70. 8.12.3 AstraZeneca Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AstraZeneca Sustained-release Medicine Product Portfolio
  72. 8.12.5 AstraZeneca Recent Developments
  73. 8.13 Collegium Pharmaceutical, Inc
  74. 8.13.1 Collegium Pharmaceutical, Inc Company Information
  75. 8.13.2 Collegium Pharmaceutical, Inc Business Overview
  76. 8.13.3 Collegium Pharmaceutical, Inc Sustained-release Medicine Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Collegium Pharmaceutical, Inc Sustained-release Medicine Product Portfolio
  78. 8.13.5 Collegium Pharmaceutical, Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst